Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Will Novo’s LEADER Trial Move GLP-1 To The Front Line In High-Risk Diabetes?

This article was originally published in The Pink Sheet Daily

Executive Summary

Novo Nordisk sets its sights on GLP-1 expansion after Victoza scores in CV outcomes trial, but docs want the full dataset to understand the robustness and implications of results.


Related Content

Diabetes Drug Safety Might Be Best Assessed With Real-World Data
FDA’s Zetia/Vytorin Rejection Leaves Cholesterol Drug Sponsors In Limbo
Sanofi's Lixisenatide Gets Clean Bill Of Health On CV Safety, Heart Failure


Related Companies